Heterologous CBS-based eye drops represent a promising therapeutic approach in the healing of severely injured corneal epithelium and in subjective symptom relief. These drops can be obtained as readily available and quality-controlled blood derivative from cord blood banks on a routine basis.

No abstract

No abstract

No abstract

No abstract

No abstract

Purpose Bortezomib (Velcade) is an antineoplastic drug widely used in the treatment of multiple myeloma. According to the manufacturer, once reconstituted, bortezomib is only stable for 8 h at 25°C. The aim of this study was to evaluate the stability of reconstituted bortezomib stored in original vials and syringes at 4°C and 28°C, for up to 10 days. Methods Samples were prepared by dissolving 3.5 mg of bortezomib powder in 3.5 ml of physiological saline (final concentration 1 mg/ml) under routine clinical conditions. Samples were stored in vials or syringes at 4°C and 28°C with photoprotection, and drug stability was analysed by high performance liquid chromatography. results Bortezomib was stable in both original vials and syringes for up to 10 days at 4°C with photoprotection. Furthermore, it was stable for up to 8 days at 28°C in original vials with photoprotection. conclusions Our results showed an extended stability of bortezomib prepared under routine clinical conditions and stored at 4°C, which could make an important contribution towards reducing drug waste and, consequently, improving cost efficiency.

No abstract